Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

被引：3
|
作者：
Spencer, Andrew [1 ]
Iversen, Katrine Fladeland [2 ]
Dhakal, Binod [3 ]
Creignou, Maria [4 ]
Chen, Jenny [5 ]
Hiemstra, Ida H. [6 ]
Bosgra, Sieto [6 ]
Badani, Avani [5 ]
Breij, Esther C. W. [6 ]
Brady, Lauren K. [5 ]
Sasser, A. Kate [5 ]
Malmberg, Anders [7 ]
Gregersen, Henrik [8 ]
Hansson, Markus [9 ]
Broijl, Annemiek [10 ]
Mateos, Maria-Victoria [11 ]
Plesner, Torben [2 ]
机构：
[1] Alfred Hosp, Melbourne, Vic, Australia
[2] Vejle Hosp, Vejle, Denmark
[3] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA
[4] Karolinska Univ Hosp, Dept Hematol, Huddinge, Sweden
[5] Genmab, Princeton, NJ USA
[6] Genmab, Utrecht, Netherlands
[7] Genmab, Copenhagen, Denmark
[8] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark
[9] Aalborg Univ Hosp, Aalborg, Denmark
[10] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands
[11] USAL CSIC, Hosp Univ Salamanca, IBSAL, IBMCC, Salamanca, Spain
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159116
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7320 / 7321
页数：2
相关论文
共 50 条
  • [31] Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Nooka, Ajay K.
    O'Donnell, Elizabeth K.
    Weller, Edie A.
    Couture, Nicole R.
    Wallace, Ellen E.
    Burke, Jill N.
    Harrington, Cynthia C.
    Puccio-Pick, Marie
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Raje, Noopur S.
    BLOOD, 2015, 126 (23)
  • [32] A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
    Berenson, James R.
    Klein, Leonard
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Ou, Ying
    Cartmell, Alan
    BLOOD, 2013, 122 (21)
  • [33] An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
    Kropff, Martin
    Kienast, Joachim
    Bisping, Guido
    Berdel, Wolfgang E.
    Gaschler-Markefski, Birgit
    Stopfer, Peter
    Stefanic, Martin
    Munzert, Gerd
    ANTICANCER RESEARCH, 2009, 29 (10) : 4233 - 4238
  • [34] Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
    Jing, Hongmei
    Yang, Li
    Qi, Junyuan
    Qiu, Lugui
    Fu, Chengcheng
    Li, Junmin
    Yang, Min
    Qi, Ming
    Fan, Ni
    Ji, Jia
    Lu, Jiajia
    Li, Yunan
    Jin, Jie
    ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2679 - 2690
  • [35] Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
    Krishnan, Amrita Y.
    Patel, Krina K.
    Hari, Parameswaran
    Jagannath, Sundar
    Niesvizky, Ruben
    Silbermann, Rebecca W.
    Berg, Deborah
    Lin, Jianchang
    Fedyk, Eric Robert
    Palumbo, Antonio
    Stockerl-Goldstein, Keith E.
    BLOOD, 2019, 134
  • [36] Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Maharaj, Michele
    Oliver, Katherine
    Callander, Natalie Scott
    BLOOD, 2016, 128 (22)
  • [37] Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).
    Wong, Lilly
    Jimenez Nunez, Maria Dolores
    Bahlis, Nizar J.
    Vangsted, Annette J.
    Ramasamy, Karthik
    Trudel, Suzanne
    Martinez, Joaquin
    Mateos, Maria-Victoria
    Rodriguez Otero, Paula
    Lonial, Sagar
    Popat, Rakesh
    Oriol, Albert
    Karanes, Chatchada
    Orlowski, Robert Z.
    Berdeja, Jesus G.
    Wang, Maria
    Lamba, Manisha
    Pourdehnad, Michael
    Pierce, Daniel W.
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
    Ghobrial, Irene M.
    Weller, Edie
    Vij, Ravi
    Munshi, Nikhil C.
    Banwait, Ranjit
    Bagshaw, Meghan
    Schlossman, Robert
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Laubach, Jacob
    Jakubowiak, Andrzej J.
    Maiso, Patricia
    Roccaro, Aldo
    Armand, Philippe
    Dollard, Akari
    Warren, Diane
    Harris, Brianna
    Poon, Tiffany
    Sam, Amy
    Rodig, Scott
    Anderson, Kenneth C.
    Richardson, Paul G.
    LANCET ONCOLOGY, 2011, 12 (03) : 263 - 272
  • [39] Daratumumab, a CD38 mab, for the treatment of relapsed/refractory multiple myeloma patients: Preliminary efficacy data from a multicenter phase I/II study.
    Plesner, Torben
    Lokhorst, Henk M.
    Gimsing, Peter
    Nahi, Hareth
    Lisby, Steen
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] A PHASE IB DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    San Miguel, J.
    Sezer, O.
    Siegel, D.
    Guenther, A.
    Blade, J.
    Prosser, I.
    Hazell, K.
    Bengoudifa, R.
    Klebsattel, M.
    Bourquelot, P.
    Cavo, M.
    Goebeler, M.
    Niederweiser, D.
    Milder, M.
    Boccadoro, M.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 155 - 155
12345